Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC)

BJU International

Volumn 110, Issue 9, 2012, Pages 1276-1282

  Silberstein, Jonathan L ^a   Adamy, Ari ^a   Maschino, Alexandra C ^a   Ehdaie, Behfar ^a   Garg, Tullika ^a   Favaretto, Ricardo L ^a   Ghoneim, Tarek P ^a   Motzer, Robert J ^a   Russo, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clavien; complications; metastatic; nephrectomy; renal cell carcinoma; sunitinib

Indexed keywords

CALCIUM; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CALCIUM BLOOD LEVEL; DISEASE CLASSIFICATION; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC DISORDER; METASTASIS; METASTASIS RESECTION; MORBIDITY; NEPHRECTOMY; NEUROLOGIC DISEASE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VALIDATION STUDY; WOUND COMPLICATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; POSTOPERATIVE COMPLICATIONS; PYRROLES; RISK ASSESSMENT; RISK FACTORS;

EID: 84867725031     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11103.x     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Sun M, Thuret R, Abdollah F, et al,. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 2011; 59: 135-41
3. Flanigan RC, Salmon SE, Blumenstein BA, et al,. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-9
4. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-70
5. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24
6. Motzer RJ, Hutson TE, Tomczak P, et al,. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90
7. Russo P, O'Brien MF,. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 2008; 35: 679-86
8. Russo P,. Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol 2010; 28: 295-301
9. Russo P, Synder M, Vickers A, Kondagunta V, Motzer R,. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. ScientificWorldJournal 2007; 7: 768-78
10. Dindo D, Demartines N, Clavien PA,. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-13
11. Shabsigh A, Korets R, Vora KC, et al,. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55: 164-74
12. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J,. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40
13. Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC,. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243: 373-9
14. Abdollah F, Sun M, Thuret R, et al,. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol 2011; 18: 2988-96
15. Schag CC, Heinrich RL, Ganz PA,. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2: 187-93
16. Rabadan AT, Hernandez D, Eleta M, et al,. Factors related to surgical complications and their impact on the functional status in 236 open surgeries for malignant tumors in a Latino-American hospital. Surg Neurol 2007; 68: 412-20
17. Asano K, Nakano T, Takeda T, Ohkuma H,. Risk factors for postoperative systemic complications in elderly patients with brain tumors. Clinical article. J Neurosurg 2009; 111: 258-64
18. Lowrance WT, Yee DS, Savage C, et al,. Complications after radical and partial nephrectomy as a function of age. J Urol 2010; 183: 1725-30
19. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P,. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006; 24: 3101-6
20. Margulis V, Matin SF, Tannir N, et al,. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008; 180: 94-8
21. Culp SH, Tannir NM, Abel EJ, et al,. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010; 116: 3378-88